levoketoconazole Recorlev
Selected indexed studies
- Ketoconazole. (, 2006) [PMID:30000287]
- Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. (Expert Rev Endocrinol Metab, 2021) [PMID:34380370]
- Cushing's disease: adrenal steroidogenesis inhibitors. (Pituitary, 2022) [PMID:36036308]
_Worker-drafted node — pending editorial review._
Connections
levoketoconazole Recorlev is a side effect of
Sources
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome. (2026) pubmed
- Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. (2021) pubmed
- Cushing's disease: adrenal steroidogenesis inhibitors. (2022) pubmed
- Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. (2021) pubmed
- Efficacy and Safety of Levoketoconazole in Managing Cushing's Syndrome: A Systematic Review. (2024) pubmed
- Ketoconazole. (2006) pubmed
- Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. (2021) pubmed
- Medical Management of Cushing Disease. (2019) pubmed
- Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. (2019) pubmed
- How best to monitor the specific side effects of medical treatments of Cushing's disease. (2022) pubmed